Baseline patient characteristics
| Characteristic | Patients (n=14) |
| Age (years) | |
| Mean | 60 |
| Median (range) | 60.5 (45–77) |
| Race/ethnicity (n (%)) | |
| Asian | 1 (7) |
| Black or African American | 2 (14) |
| Hispanic white | 4 (28) |
| Non-Hispanic white | 7 (50) |
| ECOG PS (n (%)) | |
| 0 | 7 (50) |
| 1 | 7 (50) |
| Platinum sensitivity (n (%)) | |
| Resistant | 12 (86) |
| Refractory | 2 (14) |
| Histology (n (%)) | |
| High grade serous | 12 (86) |
| Clear cell | 1 (7) |
| Mixed serous/clear cell | 1 (7) |
| No of prior therapies (median (range)) | 3 (1–5) |
| Prior treatment with PARP inhibitors (n (%)) | 7 (50) |
| Prior treatment with bevacizumab (n (%)) | 6 (43) |
ECOG PS, Eastern Cooperative Oncology Group (ECOG) performance status; PARP, poly (ADP-ribose) polymerase.